Ophthotech Reports First Quarter 2014 Financial Results and Provides Business … – Business Wire (press release)

Ophthotech Reports First Quarter 2014 Financial Results and Provides Business
Business Wire (press release)
Ophthotech announced its strategy to expand its Fovista anti-PDGF therapy program beyond the pivotal Phase 3 clinical trials in wet AMD and to advance its Zimura™ program in both dry and wet AMD. Zimura™ is an inhibitor of complement factor C5.

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment